ENASIDENIB MESYLATE
| Brand name | IDHIFA |
|---|---|
| Active ingredient | ENASIDENIB MESYLATE |
| Strength | EQ 50MG BASE |
| Dosage form | TABLET |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | August 2017 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 9732062 | September 2034 | substance |
| 10093654 | August 2034 | substance, product |
| 9738625 | August 2034 | substance |
| 9512107 | January 2033 | substance, product |
| 10294215 | January 2033 | product |
| 10610125 | June 2030 | use U-2087 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.